Articles related to DYSLIPIDEMIA

The FDA approved olezarsen (Tryngolza), an apoC-III antisense inhibitor, as an adjunct to diet for reducing triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia, based on phase 3 data showing an 85% reduction in pancreatitis events compared with placebo.

A 4-week randomized trial in 20 obese men with hypercholesterolemia found that intermittent hypoxic training combined with caloric restriction produced greater reductions in LDL-C, total cholesterol, and triglycerides compared with normoxic training under identical dietary conditions.

Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.

Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

ACC/AHA’s 2026 dyslipidemia guideline reintroduces LDL-C and non-HDL-C treatment goals, replaces Pooled Cohort Equations with PREVENT, and recommends one-time lipoprotein(a) measurement in all adults.

According to the Gould Registry, in 5,006 patients with ASCVD, only one in three patients had LDL cholesterol even less than 70mg/dl.